Vitamin C

Of Vitamin C, and of the Offices It Holds as Cofactor, Antioxidant, and Quiet Regulator of the Genome

A scholarly essay drawn from academic research on mechanism, immunity, gene regulation, fatal disease, and the question of dose, including the counsel of Linus Pauling

It is not unfitting to consider a simple sugar-acid that the human body cannot make, and without which the sailor once perished of scurvy. Vitamin C—ascorbic acid, or ascorbate at physiological pH—is an essential electron donor. Humans lost a functional gene for gulonolactone oxidase and must therefore take the molecule from food or from the chemist. That necessity has tempted both the cautious dietitian and the bold advocate. The former sets a daily allowance in tens of milligrams; the latter, following Linus Pauling, has spoken of grams. Between those poles lies a body of university work that is richer in mechanism than in miracle, and that is the subject of this essay.

Of the mechanisms by which the molecule works

Ascorbate donates electrons. From that single chemical habit three families of office follow. First, it is a water-soluble antioxidant: it reduces reactive oxygen species, regenerates vitamin E at the membrane, and protects proteins, lipids, and nucleic acids from oxidation. Second, it is a cofactor that keeps iron and copper in the reduced state required by a large family of Fe²⁺- and α-ketoglutarate-dependent dioxygenases. Third, through those same enzymes, it reaches into chromatin and into the oxygen-sensing machinery of the cell.

The oldest enzymatic office is collagen. Prolyl and lysyl hydroxylases in the endoplasmic reticulum need ascorbate to hydroxylate nascent collagen chains so that the triple helix may fold, secrete, and cross-link. Without that cofactor, the matrix of skin, vessel, bone, and wound fails—the pathology of scurvy. Related dioxygenases complete carnitine biosynthesis and certain peptide hormones. A second set of prolyl hydroxylases marks the hypoxia-inducible factor HIF-1α for destruction when oxygen is plentiful. When ascorbate is scarce, HIF-1α persists even in air, and a hypoxia-like transcriptional programme is switched on. Thus the same chemistry that builds collagen also restrains a master regulator of angiogenesis and metabolism.

In the nucleus the same logic governs gene regulation. The ten-eleven translocation (TET) enzymes oxidise 5-methylcytosine toward 5-hydroxymethylcytosine and onward toward demethylation; Jumonji-domain histone demethylases remove repressive methyl marks from histones. Both classes require Fe²⁺ and are markedly more active when ascorbate is supplied as cofactor. University work has shown that this epigenetic circuit licenses osteoblast gene programmes, favours T-cell differentiation, and influences stem-cell state. Vitamin C does not “turn genes on” as a transcription factor would; it restores the catalytic fitness of the enzymes that open chromatin so that other programmes may speak.

Uptake is not casual. Enterocytes and many tissues import ascorbate through sodium-dependent vitamin C transporters (SVCT1 and SVCT2). Dehydroascorbic acid, the oxidised form, may enter through glucose transporters and be reduced again inside the cell. Leukocytes concentrate ascorbate to levels fifty- to a hundred-fold above plasma. Neutrophils may reach one to two millimolar. That gradient is itself a clue that immune cells treat the molecule as more than a circulating antioxidant.

Of the immune system, and whether the molecule strengthens it

Deficiency impairs immunity; that much is not in dispute. Reviews from Carr and Maggini, and from university groups studying leukocyte biology, describe a coherent set of supports. Epithelial barriers depend on collagen and on oxidant scavenging in the skin. Neutrophils use ascorbate in chemotaxis, phagocytosis, and the controlled generation of reactive oxygen species for microbial killing; they also need it for timely apoptosis so that macrophages may clear spent cells and spare the tissue from necrosis and NET-driven injury. Natural killer activity and lymphocyte proliferation have been reported to improve when depleted subjects are repleted. T-cell maturation is influenced by TET-dependent demethylation. In inflammation, ascorbate can moderate some cytokine signals, though the effect varies by cell type and dose.

Does it “strengthen” the immune system of a well-fed person? Here the evidence is more modest. Maximal leukocyte ascorbate is already approached at dietary intakes near 100 milligrams a day. Cochrane-style syntheses of community trials show that routine oral supplementation at or above 200 milligrams does not reduce the incidence of the common cold in the general population. It does, on average, shorten duration by about eight percent in adults and fourteen percent in children when taken regularly. In people under brief extreme physical stress—soldiers, skiers, marathoners—incidence has fallen by about half. Infection itself consumes ascorbate; plasma levels fall in sepsis and in severe respiratory illness, which is why intensive-care trials have tested intravenous doses that oral tablets cannot match. The fair sentence is this: vitamin C is necessary to a competent immune system, and repletion helps the depleted; megadose oral supplementation does not confer a general armour against everyday colds.

Of genetic activation, more closely considered

The phrase “genetic activation” is easily overstated. Ascorbate is not a hormone that occupies response elements as vitamin D does. Its genomic influence is enzymatic and epigenetic. By keeping TET and Jumonji demethylases catalytic, it lowers DNA and histone methylation at selected loci and thereby permits transcription that was previously repressed. In bone-marrow stromal cells from ascorbate-deficient animals, this circuit is required for the expression of osteogenic transcription factors, collagens, and mineralisation genes—an epigenetic office distinct from collagen hydroxylation itself. In immune development, the same demethylation supports lineage programmes. In tumours, high intracellular ascorbate can, in experimental systems, restore TET activity in cells that have lost it, and pharmacologic intravenous concentrations can also generate hydrogen peroxide in the extracellular space; those are laboratory and early clinical observations, not a licence to treat cancer with grocery-store tablets.

Of fatal disease, and of what the cohorts and the trials allow us to say

Observational epidemiology is consistent and confounded. A systematic review and dose–response meta-analysis in the American Journal of Clinical Nutrition, drawing on sixty-nine prospective studies, found that each additional 100 milligrams a day of dietary vitamin C was associated with relative risks of 0.88 for coronary heart disease, 0.92 for stroke, 0.89 for cardiovascular disease, 0.93 for total cancer, and 0.89 for all-cause mortality. Each 50 micromole per litre rise in blood ascorbate was associated with still lower risks: 0.74, 0.70, 0.76, 0.74, and 0.72 respectively. Highest versus lowest dietary vitamin C has been linked to about a 21 percent lower cardiovascular mortality in another synthesis. Blood concentrations track fruit and vegetable intake, smoking, and social position; they are not a randomised assignment of tablets.

Randomised supplementation tells a cooler story. Large antioxidant-vitamin trials did not show that oral vitamin C, given to generally nourished adults, reliably prevents cancer or cardiovascular death. A 2023 systematic review of forty-four randomised trials (26,540 participants) reported a pooled relative risk of 0.87 for all-cause mortality with oral or intravenous vitamin C, but trial-sequential analysis did not confirm the result. The sepsis subgroup did: relative risk 0.74, and that signal survived sequential analysis. A COVID-19 mortality difference was suggested and not yet confirmed. Cancer mortality in those trials was not significantly reduced. A later synthesis of intravenous vitamin C in malignant disease (eight studies, 2,722 adults) reported a longer median overall survival, with moderate certainty and important caveats: doses ranged from grams per day to more than a gram per kilogram; cohort studies weighed more than randomised trials; the finding is not a completed proof that intravenous ascorbate is standard cancer care.

History still shadows the cancer question. Pauling and Cameron reported longer survival in advanced cancer with about 10 grams a day, often given intravenously and then by mouth. Three Mayo Clinic randomised trials of 10 grams a day by mouth found no survival benefit. Pharmacokinetic work later showed why the designs were not equivalent: oral dosing saturates intestinal transporters and is constrained by renal excretion; intravenous infusion can raise plasma ascorbate into the millimolar range, where pro-oxidant chemistry against tumour cells becomes plausible. The Mayo trials therefore refute oral megadose as a general cancer treatment; they do not close the separate question of carefully protocolled intravenous use, which remains investigational.

Of Linus Pauling, and of nine grams a day

Linus Pauling, twice a Nobel laureate, argued from evolutionary comparison and from a small set of early cold trials that the recommended allowance—then set near the scurvy-prevention floor—was far too low. He published on ascorbic acid and the common cold in 1970 and 1971, and later on cancer and longevity. His personal intake was reported at times as 12 grams a day, and as high as 18 grams, with still larger amounts at the first hint of a cold. The figure of nine grams a day belongs to that same orthomolecular register: a dose two orders of magnitude above the present adult recommended dietary allowance, and several times the present tolerable upper intake level for ordinary oral use.

What subsequent research has shown is not that Pauling was idle, but that he over-read a thin literature and under-weighted later, larger trials. Pooled analyses of the biggest community cold studies, using a gram a day or more, found no reduction in incidence (pooled risk ratio about 0.99). Duration and severity shrink modestly when supplementation is regular. The Ritzel ski-school trial that weighed heavily in Pauling’s early argument has not generalised to ordinary civilian life. For cancer, oral 10-gram regimens failed in randomised hands. For everyday mortality, diet and blood levels predict better outcomes; gram-dose pills have not reproduced that prediction in healthy populations.

Of the recommended dose, as the laboratories now measure it

The United States recommended dietary allowance is 90 milligrams a day for adult men and 75 milligrams for adult women, with an additional 35 milligrams for smokers, and higher figures in pregnancy and lactation. Those numbers were raised from older scurvy-prevention targets and are based, in part, on the intake that saturates neutrophils while limiting unused ascorbate in the urine. Tissue and plasma studies associated with Mark Levine and the National Institutes of Health showed that plasma ascorbate rises steeply up to about 200 milligrams a day by mouth and then flattens; above roughly 400 milligrams, further oral increments are largely excreted. Leukocyte stores are already near maximal at about 100 milligrams a day in healthy volunteers. The tolerable upper intake level for adults is 2,000 milligrams a day, set chiefly to limit osmotic diarrhoea and gastrointestinal discomfort. High oral doses can raise urinary oxalate; whether they raise stone risk in ordinary use remains unsettled and is a reason for caution in those predisposed to oxalate nephrolithiasis.

Nine grams a day therefore sits well above both the allowance and the upper level. It is not required to saturate ordinary tissues. It is not supported as a population regimen to prevent colds or to lengthen life. It may be used, under medical attention, in short therapeutic experiments or in intravenous protocols whose pharmacokinetics differ from tablets. For the commonwealth of the healthy, the academic literature points to a diet rich in fruit and vegetables—often 200 milligrams of vitamin C a day or more from food—correction of true deficiency, and scepticism toward the notion that more remains better once the transporters are full.

A closing measure

Vitamin C is a cofactor, an antioxidant, and an epigenetic enabler. It strengthens immunity when the body is empty of it, and it supports barriers, phagocytes, and lymphocytes by mechanisms that university reviews have mapped with care. It regulates gene activity not as a nuclear receptor but as the keeper of TET and Jumonji enzymes and of HIF hydroxylases. Higher dietary intake and higher blood levels are associated with fewer fatal cardiovascular events, less recorded cancer, and lower all-cause mortality; those associations have not been cleanly reproduced by megadose pills in the well-nourished. Pauling’s nine grams was a bold conjecture from a great chemist. The research that followed has kept the molecule’s dignity and trimmed the dose. Measure the diet, treat scurvy and depletion without delay, reserve pharmacologic ascorbate for trials and for the severely ill, and do not ask a saturated transporter to perform a miracle it cannot hold.

Principal sources (academic and consortium studies)

Carr and Maggini, Vitamin C and Immune Function. Ang, Pullar, Currie, Vissers, vitamin C in immune-cell function, inflammation, and cancer. Cimmino, Neel, and Aifantis, vitamin C in stem-cell reprogramming and Fe²⁺/α-ketoglutarate-dependent dioxygenases. Thaler and colleagues, vitamin C epigenetically controls osteogenesis. Aune et al., American Journal of Clinical Nutrition meta-analysis of dietary and blood antioxidants and mortality. Jayedi et al., Public Health Nutrition, vitamin C and cardiovascular mortality. Xu et al., oral or intravenous vitamin C and mortality, forty-four-trial review. Cochrane and Hemilä syntheses of vitamin C and the common cold. Levine and National Institutes of Health pharmacokinetic studies of oral ascorbate saturation. Pauling, Proceedings of the National Academy of Sciences, ascorbic acid and the common cold. Cameron and Pauling case series; Mayo Clinic randomised trials of oral megadose vitamin C in advanced cancer.